secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009282
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC
------------------------------------------------------------------------

- Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
- No dose-related increases in adverse events; neutropenia consistent with palbociclib plus endocrine therapy profile.
- Partial responses observed in 5 patients (1 confirmed, 4 unconfirmed); clinical benefit rate 42% (5/12 CBR-eligible).
- 59% of patients remain on treatment as of March 8, 2023 data cut-off; enrollment ongoing toward ~45 patients.
- OP-1250 showed favorable PK: 8-day half-life, dose-proportional exposure, no effect on palbociclib levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/0001558370-23-009282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/olma-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer